Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes
- 383 Downloads
This study aimed to evaluate the feasibility, local efficacy and long-term outcomes of microwave (MW) ablation for the treatment of hepatocellular carcinoma (HCC) that met up-to-seven criteria.
Between January 2007 and January 2012, 142 HCC patients with 294 nodules, which conformed to up-to-seven criteria, were enrolled into this retrospective study. All patients were followed up for more than 3 years after receiving MW ablation. Technical success, complications, local tumour progression (LTP) and distant recurrence (DR) were monitored. Recurrence-free survival (RFS), overall survival (OS) and prognostic factors were analysed.
Primary technical efficacy was achieved in 95.2% (280/294) of the carcinomatous nodules, and major complications occurred in four (2.8%) patients. Among the 294 tumours, LTP was observed in 44 (15.0%) tumours. Among the 142 patients, DR was observed in 97 (68.3%) patients. The estimated OS rates after MW ablation at 1, 3 and 5 years were 97.2%, 75.4% and 50.6%, respectively; and the corresponding RFS rates were 76.1%, 33.1% and 19.5%, respectively.
MW ablation is a safe and effective treatment with a high rate of primary technical efficacy for patients with HCC that met up-to-seven criteria.
• The first study expanding MW ablation to HCC category beyond Milan criteria.
• The first report that used up-to-seven criteria as indications for MW ablation.
• HCC of up-to-seven criteria viewed as a subgroup of BCLC stage B.
• MW ablation is safe and effective for treating HCC within up-to-seven criteria.
• MW ablation is preferable in treating unresectable HCC within up-to-seven criteria.
KeywordsHepatocellular carcinoma Microwave ablation Up-to-seven criteria Therapeutic efficacy Prognostic factors
Compliance with ethical standards
The scientific guarantor of this publication is Guojun Qian.
Conflict of interest
The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
The authors state that this work has not received any funding.
Statistics and biometry
One of the authors: Yun Xu has significant statistical expertise.
Institutional review board approval was obtained.
Written informed consent was obtained from all subjects (patients) in this study.
Study subjects or cohorts overlap
No study subjects or cohorts have been previously reported.
performed at one institution
- 4.Takuma Y, Takabatake H, Morimoto Y et al (2013) Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology 269:927–937CrossRefPubMedGoogle Scholar
- 18.Biolato M, Marrone G, Racco S et al (2010) Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmaco Sci 14:356–362Google Scholar
- 35.Goh BKP, Chow PKH, Teo JY et al (2014) Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg 18:1477–1485CrossRefPubMedGoogle Scholar